Payment overview · 2025
General Payments
$1,751.37
99 reported records · 18 companies
Healthcare provider profile · identity verified
John R Hansen, MD
Allopathic & Osteopathic Physicians|Family Medicine · OVERLAND PARK, KS · NPI 1073521977
Verified facts
What the public records show
CMS Open Payments records show John R Hansen, MD received $1,751.37 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $414.48 | 23.7% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.12 | 14.9% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $240.15 | 13.7% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.30 | 9.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.13 | 8.2% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $104.56 | 6.0% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $88.43 | 5.0% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $58.93 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.92 | 3.1% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $47.88 | 2.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.29 | 1.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $29.68 | 1.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $28.75 | 1.6% | 2 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $19.66 | 1.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.90 | 1.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.89 | 1.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.76 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.54 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,751.37 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $220.60 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $203.50 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $185.39 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.28 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $124.61 | 8 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $124.61 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $124.61 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.01 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.01 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.76 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $115.54 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $104.56 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $89.29 | 8 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $88.43 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.26 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $68.87 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $58.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $54.92 | 4 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $47.88 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $29.68 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.25 | 2 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 66 |
| Lisinopril | Lisinopril | 214 | 61 |
| Alprazolam | Alprazolam | 201 | 39 |
| Omeprazole | Omeprazole | 190 | 51 |
| Losartan Potassium | Losartan Potassium | 184 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 11 |
| Meloxicam | Meloxicam | 144 | 43 |
| Simvastatin | Simvastatin | 135 | 37 |
| Gabapentin | Gabapentin | 125 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 29 |
| Metformin Hcl | Metformin Hcl | 100 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 24 |
| Allopurinol | Allopurinol | 82 | 21 |
| Furosemide | Furosemide | 76 | 25 |
| Methylprednisolone | Methylprednisolone | 73 | 60 |
| Temazepam | Temazepam | 73 | 11 |
| Tramadol Hcl | Tramadol Hcl | 72 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 19 |
| Ezetimibe | Ezetimibe | 71 | 20 |
| Bupropion Xl | Bupropion Hcl | 68 | 17 |
| Lorazepam | Lorazepam | 67 | 12 |
| Trazodone Hcl | Trazodone Hcl | 67 | 16 |
| Potassium Chloride | Potassium Chloride | 66 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 15 |
| Sertraline Hcl | Sertraline Hcl | 64 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 20 |
| Diazepam | Diazepam | 61 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 16 |
| Metformin Hcl Er | Metformin Hcl | 58 | 15 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Prednisone | Prednisone | 56 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 19 |
| Carvedilol | Carvedilol | 54 | 19 |
| Eliquis | Apixaban | 49 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Jardiance | Empagliflozin | 42 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Fentanyl | Fentanyl | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 11 |
| Clonazepam | Clonazepam | 39 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 13 |
| Montelukast Sodium | Montelukast Sodium | 36 | 13 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 25 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Testosterone | Testosterone | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 16 |
| Fluconazole | Fluconazole | 21 | 13 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Famotidine | Famotidine | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Baclofen | Baclofen | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,751.37 · 99 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSENSE, AIRSUPRA, BREZTRI, COMIRNATY, CREON, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Flector, General - Therapies, JARDIANCE, JATENZO, LINZESS, Licart, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SYNTHROID, Senza, Tirosint, Tymlos, UBRELVY, UNITHROID, VOQUEZNA, Veozah, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error